Effect of HIV aspartyl protease inhibitors on experimental infection with a cystogenic Me49 strain of Toxoplasma gondii

References

• Dubey JP. Toxoplasmosis of Animals and Humans. Second ed. Boca Raton, Florida: CRC Press Inc; 2010. p. 1–313.
   Google Scholar
• Pereira-Chioccola VL, Vidal JE, Su C. Toxoplasma gondii infection and cerebral toxoplasmosis in HIV-infected patients. Future Microbiol. 2009;4:1363–1379.
   PubMed Web of Science ®Google Scholar
• Elsheikha HM. Congenital toxoplasmosis: priorities for further health promotion action. Public Health. 2008;122:335–353.
   PubMed Web of Science ®Google Scholar
• Chu KB, Quan FS. Advances in Toxoplasma gondii vaccines: current strategies and challenges for vaccine development. Vaccines (Basel). 2021;9:413–428.
   PubMed Web of Science ®Google Scholar
• Harker KS, Ueno N, Lodoen MB. Toxoplasma gondii dissemination: a parasite’s journey through the infected host. Parasite Immunol. 2015;37(3):141–149.
   PubMed Web of Science ®Google Scholar
• Wohlfert EA, Blader IJ, Wilson EH. Brains and brawn: toxoplasma infections of the central nervous system and skeletal muscle. Trends Parasitol. 2017;33:519–531.
   PubMed Web of Science ®Google Scholar
• Cerutti A, Blanchard N, Besteiro S. The bradyzoite: a Key developmental stage for the persistence and pathogenesis of toxoplasmosis. Pathogens (Basel. Switzerland). 2020;9(3):234.
   Web of Science ®Google Scholar
• Suzuki Y, Sa Q, Gehman M, et al. Interferon-gamma- and perforin-mediated immune responses for resistance against Toxoplasma gondii in the brain. Expert Rev Mol Med. 2011;4:13–31.
   Google Scholar
• Rodriguez JB, Szajnman SH. New antibacterials for the treatment of toxoplasmosis; a patent review. Expert Opinion on Therapeutic Patents. 2012;22(3):311–333.
   PubMed Web of Science ®Google Scholar
• Djurkovi-Djakovi O, Milenkovi V, Nikoli A, et al. Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii. J Antimicrob Chemother. 2002;50:981–987.
   PubMed Web of Science ®Google Scholar
• Chirgwin K, Hafner R, Leport C, et al. Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. Clin Infect Dis. 2002;34:1243–1250.
   PubMed Web of Science ®Google Scholar
• Nagamune K, Beatty WL, Sibley LD. Artemisinin induces calcium-dependent protein secretion in the protozoan parasite Toxoplasma gondii. Eukaryot Cell. 2007;6:2147–2156.
   PubMed Web of Science ®Google Scholar
• Innes EA. Vaccination against Toxoplasma gondii: an increasing priority for collaborative research? Expert Rev. Vaccines (Basel). 2010;9:1117e1119.
   Web of Science ®Google Scholar
• Antczak M, Dzitko K, Długońska H. Human toxoplasmosis: searching for novel chemotherapeutics. Biomed Pharmacother. 2016;82:677–684.
   PubMed Web of Science ®Google Scholar
• Abou-El-Naga IF, Mogahed NMFH. Repurposing auranofin for treatment of experimental cerebral toxoplasmosis. Acta Parasitol. 2021;1:1–10.
   Google Scholar
• de Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009;33:307–320.
   PubMed Web of Science ®Google Scholar
• Abou-El-Naga IF, Mady RF, Mogahed NMFH. In vitro effectivity of three approved drugs and their synergistic interaction against Leishmania infantum. Biomedica. 2020;1:89–101.
   Google Scholar
• Parikh S, Gut J, Istvan E, et al. Antimalarial activity of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2005;49:2983–2985.
   PubMed Web of Science ®Google Scholar
• Sangenito LS, Menna-Barreto RFS, Oliveira AC, et al. Primary evidence of the mechanisms of action of HIV aspartyl peptidase inhibitors on Trypanosoma cruzi trypomastigote forms. Int J Antimicrob Agents. 2018;52:185–194.
   PubMed Web of Science ®Google Scholar
• Monzote L, Rodríguez M, Alfonso Y, et al. Antiretroviral activity of protease inhibitors against Toxoplasma gondii. Rev Inst Med Trop. 2013;55:65–67. Sao Paulo.
   PubMed Web of Science ®Google Scholar
• Abou-El-Naga IF, El Kerdany ED, Mady RF, et al. The effect of lopinavir/ritonavir and lopinavir/ritonavir loaded PLGA nanoparticles on experimental toxoplasmosis. Parasitol Int. 2017;66:735–747.
   PubMed Web of Science ®Google Scholar
• Fernández-Montero JV, Barreiro P, Soriano V. HIV protease inhibitors: recent clinical trials and recommendations on use. Expert Opin Pharmacother. 2009;10:1615–1629.
   PubMed Web of Science ®Google Scholar
• Shea M, Jäkle U, Liu Q, et al. A family of aspartic proteases and a novel, dynamic and cell-cycle-dependent protease localization in the secretory pathway of Toxoplasma gondii. Traffic. 2007;8:1018–1034.
   PubMed Web of Science ®Google Scholar
• Coffey MJ, Dagley LF, Seizova S, et al. Aspartyl protease 5 matures dense granule proteins that reside at the host-parasite interface in Toxoplasma gondii. mBio. 2018;9:e01796–18.
   PubMed Web of Science ®Google Scholar
• Hammoudi PM, Jacot D, Mueller C, et al. Fundamental roles of the Golgi-associated Toxoplasma aspartyl protease, ASP5, at the host-parasite interface. PLoS Pathog. 2015;11:e1005211.
   PubMed Web of Science ®Google Scholar
• El-Zawawy LA, El-Said D, Mossallam SF, et al. Preventive prospective of triclosan and triclosan-liposomal nanoparticles against experimental infection with a cystogenic ME49 strain of Toxoplasma gondii. Acta Trop. 2015;141:103–111.
   PubMed Web of Science ®Google Scholar
• Silva LA, Fernandesa MD, Machadoa AS, et al. Efficacy of sulfadiazine and pyrimethamine for treatment of experimental toxoplasmosis with strains obtained from human cases of congenital disease in Brazil. Exp Parasitol. 2019;202:7–14.
   PubMed Web of Science ®Google Scholar
• Djakovic D, Milenkovic T. Murine model of drug-induced reactivation of Toxoplasma gondii. Acta Protozool. 2001;40:99e106.
   Web of Science ®Google Scholar
• Araujo FG, Huskinson J, Remington JS, et al. Remarkable in vitro and in vivo activities of the hydroxyl-naphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob Agents Chemother. 1991;35:293–299.
   PubMed Web of Science ®Google Scholar
• Chew WK, Wah MJ, Ambu S, et al. Toxoplasma gondii: determination of the onset of chronic infection in mice and the in vitro reactivation of brain cysts. Exp Parasitol. 2012;130:22–25.
   PubMed Web of Science ®Google Scholar
• Araujo FG, Suzuki Y, Remington JS. Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice. Eur J Clin Microbiol Infect Dis. 1996;15:394–397.
   PubMed Web of Science ®Google Scholar
• Romand S, Pudney M, Derouin F. In vivo and in vitro activities of hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii. Antimicrob Agents Chemother. 1993;37:2371–2378.
   PubMed Web of Science ®Google Scholar
• Ferguson DJ, Hutchison WM, Pettersen E. Tissue cyst rupture in mice chronically infected with Toxoplasma gondii. An immunocytochemical and ultrastructural study. Parasitol Res. 1989;75:599–603.
   PubMed Web of Science ®Google Scholar
• Coffey MJ, Sleebs BE, Uboldi AD, et al. An aspartyl protease defines a novel pathway for export of Toxoplasma proteins into the host cell. eLife. 2015;4:e10809–34.
   PubMed Web of Science ®Google Scholar
• Sibley LD, Niesman IR, Parmley SF, et al. Regulated secretion of multi-lamellar vesicles leads to formation of a tubulo-vesicular network in host-cell vacuoles occupied by Toxoplasma gondii. J Cell Sci. 1995;108:1669–1677.
   PubMed Web of Science ®Google Scholar
• Roiko MS, Carruthers VB. New roles for perforins and proteases in apicomplexan egress. Cell Microbiol. 2009;11:1444–1452.
   PubMed Web of Science ®Google Scholar
• Blackman MJ. Malarial proteases and host cell egress: an ‘emerging’ cascade. Cell Microbiol. 2008;10:1925–1934.
   PubMed Web of Science ®Google Scholar
• Hobbs CV, Tanaka TQ, Muratova O, et al. HIV treatments have malaria gametocyte killing and transmission blocking activity. J Infect Dis. 2013;208:139–148.
   PubMed Web of Science ®Google Scholar
• Saag MS, Schooly RT. Antiretroviral chemotherapy. In: Remington J, Schwartz MN, editors. Current clinical topics in infectious disease. Boston: McGraw Hill Book Co; 1998. p. 154–179.
   Google Scholar
• Lemgruber L, Lupetti P, Martins-Duarte ES, et al. The organization of the wall filaments and characterization of the matrix structures of Toxoplasma gondii cyst form. Cell Microbiol. 2011;13:1920–1932.
   PubMed Web of Science ®Google Scholar
• Tu V, Tomita T, Sugi T, et al. The Toxoplasma gondii cyst wall interactome. mBio. 2020;11:e02699–19.
   PubMed Web of Science ®Google Scholar
• Fox BA, Guevara RB, Rommereim LM, et al. Toxoplasma gondii parasitophorous vacuole membrane associated dense granule proteins orchestrate chronic infection and GRA12 underpins resistance to host gamma interferon. mBio. 2019;10:e00589–19.
   PubMed Web of Science ®Google Scholar
• Guevara RB, Fox BA, Bzik DJ. Toxoplasma gondii parasitophorous vacuole membrane-associated dense granule proteins regulate maturation of the cyst wall. mSphere. 2020;5:e00851–19.
   PubMed Web of Science ®Google Scholar
• Fox BA, Falla A, Rommereim LM, et al. Type II Toxoplasma gondii KU80 knockout strains enable functional analysis of genes required for cyst development and latent infection. Eukaryotic Cell. 2011;10:1193–1206.
   PubMedGoogle Scholar
• Gold DA, Kaplan AD, Lis A, et al. The Toxoplasma dense granule proteins GRA17 and GRA23 mediate the movement of small molecules between the host and the parasitophorous vacuole. Cell Host Microbe. 2015;17:642–652.
   PubMed Web of Science ®Google Scholar
• Paredes-Santos T, Wang Y, Waldman B, et al. The GRA17 parasitophorous vacuole membrane permeability pore contributes to bradyzoite viability. Front Cell Infect Microbiol. 2019;9:321–332.
   PubMed Web of Science ®Google Scholar
• Rebello KM, Andrade-Neto VV, Zuma AA, et al. Lopinavir, an HIV-1 peptidase inhibitor, induces alteration on the lipid metabolism of Leishmania amazonensis promastigotes. Parasitology. 2018;145:1304–1310.
   PubMed Web of Science ®Google Scholar
• Kraft TE, Armstrong C, Heitmeier MR, et al. the glucose transporter pfht1 is an antimalarial target of the HIV protease inhibitor lopinavir. Antimicrob Agents Chemother. 2015;59:6203–6209.
   PubMed Web of Science ®Google Scholar
• Sa Q, Ochiai E, Tiwari A, et al. Cutting Edge: IFN-γ produced by brain-resident cells is crucial to control cerebral infection with Toxoplasma gondii. J Immunol. 2015;195:796–800.
   PubMed Web of Science ®Google Scholar
• Divanovic S, Sawtell NM, Trompette A, et al. Opposing biological functions of tryptophan catabolizing enzymes during intracellular infection. J Infect Dis. 2012;205:152–161.
   PubMed Web of Science ®Google Scholar
• Hammouda NA, Abou-El-Naga IF, Hussein ED, et al. Opsonization and intracellular killing of Toxoplasma gondii by human mononuclear phagocytes. J Egypt Soc Parasitol. 1995a;25:11–17.
   PubMedGoogle Scholar
• Hammouda NA, Rashwan EA, Hussien ED, et al. Measurement of respiratory burst of TNF and IL-1 cytokine activated murine peritoneal macrophages challenged with Toxoplasma gondii. J Egypt Soc Parasitol. 1995b;25:683–691.
   PubMedGoogle Scholar
• Wang X, Michie SA, Xu B, et al. Importance of IFN-gamma-mediated expression of endothelial VCAM-1 on recruitment of CD8+ T cells into the brain during chronic infection with Toxoplasma gondii. J Interferon Cytokine Res. 2007;27:329–338.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Wang X, Jortner BS, et al. Removal of Toxoplasma gondii cysts from the brain by perforin-mediated activity of CD8+ T cells. Am J Pathol. 2010;176:1607–1613.
   PubMed Web of Science ®Google Scholar
• Dubey JP, Lindsay DS, Speer CA. Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clinic Microbial Reviews. 1998;11:267–299.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Sher A, Yap G, et al. IL-10 is required for prevention of necrosis in the small intestine and mortality in both genetically resistant BALB/c and susceptible C57BL/6 mice following peroral infection with Toxoplasma gondii. J Immunol. 2000;164:5375–5382.
   PubMed Web of Science ®Google Scholar
• Jankovic D, Kullberg MC, Feng CG, et al. Conventional T-bet(+) Foxp3(-) Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J Exp Med. 2007;204:273–283.
   PubMed Web of Science ®Google Scholar
• Bando H, Lee Y, Sakaguchi N, et al. Toxoplasma effector GRA15-dependent suppression of IFN-γ-induced antiparasitic response in human neurons. Front Cell Infect Microbiol. 2019;9:1–11.
   PubMed Web of Science ®Google Scholar
• Pfefferkorn ER, Eckel M, Rebhun S. Interferon-gamma suppresses the growth of Toxoplasma gondii in human fibroblasts through starvation for tryptophan. Mol Biochem Parasitol. 1986a;20:215–224.
   PubMed Web of Science ®Google Scholar
• Gay G, Braun L, Brenier-Pinchart MP, et al. Toxoplasma gondii TgIST co-opts host chromatin repressors dampening STAT1-dependent gene regulation and IFN gamma-mediated host defenses. J Exp Med. 2016;213:1779–1798.
   PubMed Web of Science ®Google Scholar
• Feliu V, Vasseur V, Grover HS, et al. Location of the CD8 T cell epitope within the antigenic precursor determines immunogenicity and protection against the Toxoplasma gondii parasite. PLoS Pathog. 2013;9:e1003449.
   PubMed Web of Science ®Google Scholar
• Salvioni A, Belloy M, Lebourg A, et al. Robust control of a brain-persisting parasite through MHC I presentation by infected neurons. Cell Rep. 2019;27:254–268.
   Web of Science ®Google Scholar
• Chu HH, Chan SW, Gosling JP, et al. Continuous effector CD8(+) T cell production in a controlled persistent infection is sustained by a proliferative intermediate population. Immunity. 2016;45:159–171.
   PubMed Web of Science ®Google Scholar
• Fagone P, Mangano K, Quattrocchi C, et al. Effects of NO-hybridization on the immunomodulatory properties of the HIV protease inhibitors lopinavir and ritonavir. Basic Clin Pharmacol Toxicol. 2015;117:306–315.
   PubMed Web of Science ®Google Scholar
• Heimfarth L, Serafini MR, Martins-Filho PR, et al. Drug repurposing and cytokine management in response to COVID-19: a review. Int Immunopharmacol. 2020;88:e106947.
   PubMed Web of Science ®Google Scholar
• Alves EAR, De Miranda MG, Borges TK, et al. Anti-HIV drugs, lopinavir/ritonavir and atazanavir, modulate innate immune response triggered by Leishmania in macrophages: the role of NF-κB and PPAR-γ. Int Immunopharmacol. 2015;24:314–324.
   PubMed Web of Science ®Google Scholar